{"id":{"repo_id":"birmingham","oai_identifier":"oai:etheses.bham.ac.uk:5309"},"canonical_url":"https://search.ndltd.org/etd/birmingham/oai:etheses.bham.ac.uk:5309","repository":{"repo_id":"birmingham","name":"University of Birmingham","base_url":"https://etheses.bham.ac.uk/cgi/oai2"},"display":{"title":"Project 1: Microrna regulation of the proto-oncogene PBF And Project 2: Recognition of previously undescribed ring domain residues required for BRCA1:BARD1 and RING1B:BMI1 ubiquitin ligase activity","abstract":"PROJECT 1: In thyroid cancers there have been independent observations of the overexpression of a relatively uncharacterised proto-oncogene, PBF, as well as the deregulation of microRNAs. Therefore, the aims of this investigation were to identify whether a selection of microRNAs can regulate PBF, altering its mRNA expression and protein levels. The most striking result indicated that hsa-miR-122-5p caused a significant decrease in PBF protein levels cells despite no change in PBF mRNA expression. Furthermore, hsa-miR-124-3p and hsa-miR-506-3p also negatively regulated PBF mRNA expression and protein levels; highlighting microRNAs do have the ability to regulate PBF. PROJECT 2: BRCA1:BARD1 and RING1B:BMI1 are type I RING-type E3 ubiquitin ligases required within the final stage of the ubiquitin pathway. The mechanism of E2-ubiquitin binding and locking remains elusive in type I RING-type E3 ubiquitin ligases despite being defined in type II RING-type E3 ubiquitin ligases. We identified the requirement of a conserved residue in BRCA1:BARD1 and RING1B:BMI1 for their ubiquitin ligase activity, with further investigations into RING1B:BMI1 ubiquitin sensitivity indicating the importance of a number of residues on ubiquitin’s surface for ubiquitin ligase activity. Modelling highlighted residues in RING1B:BMI1 and ubiquitin have the potential to interact via an E2-ubiquitin binding and locking mechanism.","abstract_html":"PROJECT 1: In thyroid cancers there have been independent observations of the overexpression of a relatively uncharacterised proto-oncogene, PBF, as well as the deregulation of microRNAs. Therefore, the aims of this investigation were to identify whether a selection of microRNAs can regulate PBF, altering its mRNA expression and protein levels. The most striking result indicated that hsa-miR-122-5p caused a significant decrease in PBF protein levels cells despite no change in PBF mRNA expression. Furthermore, hsa-miR-124-3p and hsa-miR-506-3p also negatively regulated PBF mRNA expression and protein levels; highlighting microRNAs do have the ability to regulate PBF. PROJECT 2: BRCA1:BARD1 and RING1B:BMI1 are type I RING-type E3 ubiquitin ligases required within the final stage of the ubiquitin pathway. The mechanism of E2-ubiquitin binding and locking remains elusive in type I RING-type E3 ubiquitin ligases despite being defined in type II RING-type E3 ubiquitin ligases. We identified the requirement of a conserved residue in BRCA1:BARD1 and RING1B:BMI1 for their ubiquitin ligase activity, with further investigations into RING1B:BMI1 ubiquitin sensitivity indicating the importance of a number of residues on ubiquitin’s surface for ubiquitin ligase activity. Modelling highlighted residues in RING1B:BMI1 and ubiquitin have the potential to interact via an E2-ubiquitin binding and locking mechanism.","abstract_has_math":false,"creators":["Fletcher, Alice"],"institution":"University of Birmingham","degree_name":"m_rs","degree_level":"m_rs","degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2014,"date_issued":"2014-12","date_published":"2014-12","updated_at":"2026-11-19T09:28:20Z","subjects":["RC0254 Neoplasms. Tumors. Oncology (including Cancer)"],"languages":["eng"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":null,"outbound_label":null,"outbound_source":null,"record_url":null,"record_label":null,"record_kind":null,"record_source":null,"download_url":"http://etheses.bham.ac.uk//id/eprint/5309/5/Fletcher14MRes.pdf","download_label":"Download PDF","download_source":"dc:identifier.uri","access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://etheses.bham.ac.uk/cgi/oai2?verb=GetRecord&metadataPrefix=uketd_dc&identifier=oai%3Aetheses.bham.ac.uk%3A5309","prefix":"uketd_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.sponsor","label":"Sponsor","values":["na"]},{"key":"dc:creator","label":"Author","values":["Fletcher, Alice"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2014-12"]},{"key":"dc:date.issued","label":"Date","values":["2014-12"]},{"key":"dc:publisher.department","label":"Dc Publisher Department","values":["College of Medical & Dental Sciences","School of Clinical and Experiment Medicine, Department of Medicine and Medical Education"]},{"key":"dc:publisher.institution","label":"Dc Publisher Institution","values":["University of Birmingham"]},{"key":"dc:relation.isreferencedby","label":"Dc Relation Isreferencedby","values":["http://etheses.bham.ac.uk//id/eprint/5309/"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["m_rs"]},{"key":"dc:type.qualificationname","label":"Dc Type Qualificationname","values":["m_rs"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["RC0254 Neoplasms. Tumors. Oncology (including Cancer)"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.dcterms_iso639_2","label":"Language (ISO 639-2)","values":["eng"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://etheses.bham.ac.uk//id/eprint/5309/5/Fletcher14MRes.pdf"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["PROJECT 1: In thyroid cancers there have been independent observations of the overexpression of a relatively uncharacterised proto-oncogene, PBF, as well as the deregulation of microRNAs. Therefore, the aims of this investigation were to identify whether a selection of microRNAs can regulate PBF, altering its mRNA expression and protein levels. The most striking result indicated that hsa-miR-122-5p caused a significant decrease in PBF protein levels cells despite no change in PBF mRNA expression. Furthermore, hsa-miR-124-3p and hsa-miR-506-3p also negatively regulated PBF mRNA expression and protein levels; highlighting microRNAs do have the ability to regulate PBF. PROJECT 2: BRCA1:BARD1 and RING1B:BMI1 are type I RING-type E3 ubiquitin ligases required within the final stage of the ubiquitin pathway. The mechanism of E2-ubiquitin binding and locking remains elusive in type I RING-type E3 ubiquitin ligases despite being defined in type II RING-type E3 ubiquitin ligases. We identified the requirement of a conserved residue in BRCA1:BARD1 and RING1B:BMI1 for their ubiquitin ligase activity, with further investigations into RING1B:BMI1 ubiquitin sensitivity indicating the importance of a number of residues on ubiquitin’s surface for ubiquitin ligase activity. Modelling highlighted residues in RING1B:BMI1 and ubiquitin have the potential to interact via an E2-ubiquitin binding and locking mechanism."]},{"key":"dc:format","label":"Dc Format","values":["application/pdf"]},{"key":"dcterms:accessrights","label":"Dcterms Accessrights","values":["public"]},{"key":"dc:title","label":"Title","values":["Project 1: Microrna regulation of the proto-oncogene PBF And Project 2: Recognition of previously undescribed ring domain residues required for BRCA1:BARD1 and RING1B:BMI1 ubiquitin ligase activity"]}]}],"canonical_facts":{"dc:contributor.sponsor":["na"],"dc:creator":["Fletcher, Alice"],"dc:date":["2014-12"],"dc:date.issued":["2014-12"],"dc:description.abstract":["PROJECT 1: In thyroid cancers there have been independent observations of the overexpression of a relatively uncharacterised proto-oncogene, PBF, as well as the deregulation of microRNAs. Therefore, the aims of this investigation were to identify whether a selection of microRNAs can regulate PBF, altering its mRNA expression and protein levels. The most striking result indicated that hsa-miR-122-5p caused a significant decrease in PBF protein levels cells despite no change in PBF mRNA expression. Furthermore, hsa-miR-124-3p and hsa-miR-506-3p also negatively regulated PBF mRNA expression and protein levels; highlighting microRNAs do have the ability to regulate PBF. PROJECT 2: BRCA1:BARD1 and RING1B:BMI1 are type I RING-type E3 ubiquitin ligases required within the final stage of the ubiquitin pathway. The mechanism of E2-ubiquitin binding and locking remains elusive in type I RING-type E3 ubiquitin ligases despite being defined in type II RING-type E3 ubiquitin ligases. We identified the requirement of a conserved residue in BRCA1:BARD1 and RING1B:BMI1 for their ubiquitin ligase activity, with further investigations into RING1B:BMI1 ubiquitin sensitivity indicating the importance of a number of residues on ubiquitin’s surface for ubiquitin ligase activity. Modelling highlighted residues in RING1B:BMI1 and ubiquitin have the potential to interact via an E2-ubiquitin binding and locking mechanism."],"dc:format":["application/pdf"],"dc:identifier.uri":["http://etheses.bham.ac.uk//id/eprint/5309/5/Fletcher14MRes.pdf"],"dc:language.dcterms_iso639_2":["eng"],"dc:publisher.department":["College of Medical & Dental Sciences","School of Clinical and Experiment Medicine, Department of Medicine and Medical Education"],"dc:publisher.institution":["University of Birmingham"],"dc:relation.isreferencedby":["http://etheses.bham.ac.uk//id/eprint/5309/"],"dc:subject":["RC0254 Neoplasms. Tumors. Oncology (including Cancer)"],"dcterms:accessrights":["public"],"dc:title":["Project 1: Microrna regulation of the proto-oncogene PBF And Project 2: Recognition of previously undescribed ring domain residues required for BRCA1:BARD1 and RING1B:BMI1 ubiquitin ligase activity"],"dc:type":["Thesis"],"dc:type.qualificationlevel":["m_rs"],"dc:type.qualificationname":["m_rs"]},"updated_at":"2026-11-19T09:28:20Z"}